Thoughts on new drug PP405? Already reached phase 2
    Research/Science 6/9/2025

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💊 Finasteride (oral) 0.625mg daily 6 months
    the tone is 😐 neutral.

    Other terms

    PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
    View this post in the Community →

    Similar Community Posts Join

    5 / 375 results

      community The Cure isn't 5 years away; it's already here.

      in Research/Science  1005 upvotes 1 year ago
      PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

      community New article on PP405..........

      in Research/Science  111 upvotes 8 months ago
      Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

      community PP405 Might Be the Closest We Have to a Upcoming Cure

      in Technology  237 upvotes 1 year ago
      PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

      community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?

      in Treatment  23 upvotes 2 weeks ago
      A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

    Related Research

    6 / 19 results